# EDGAR Filing Document

**Accession Number:** 0001757064
**File Stem:** 0001171843-23-000442
**Filing Date:** 2023-1
**Character Count:** 8459
**Document Hash:** 7cce70d11a1029e243d9f1ec946e47cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-000442.hdr.sgml**: 20230124

**ACCESSION NUMBER**: 0001171843-23-000442

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20230124

**FILED AS OF DATE**: 20230124

**DATE AS OF CHANGE**: 20230124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Genfit S.A.
- **CENTRAL INDEX KEY:** 0001757064
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38844
- **FILM NUMBER:** 23548245

**BUSINESS ADDRESS:**
- **STREET 1:** PARC EURASANTE
- **STREET 2:** 885, AVENUE EUGENE AVINEE
- **CITY:** LOOS
- **STATE:** I0
- **ZIP:** 59120
- **BUSINESS PHONE:** 33 3 20 16 4000

**MAIL ADDRESS:**
- **STREET 1:** PARC EURASANTE
- **STREET 2:** 885, AVENUE EUGENE AVINEE
- **CITY:** LOOS
- **STATE:** I0
- **ZIP:** 59120

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report: January 24, 2023**

**Commission File Number: 001-38844**

## GENFIT S.A.
**(Translation of registrant's name into English)** 

**Parc Eurasanté**

**885, avenue Eugène Avinée**

**59120 Loos, France**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**EXHIBIT LIST**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](exh_991.htm) | [Press Release dated January 24, 2023.](exh_991.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **GENFIT S.A.** | **GENFIT S.A.** |
| Date: January 24, 2023 | By: | /s/ Pascal PRIGENT |
|  |  | Name: Pascal PRIGENT |
|  |  | Title: Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**GENFIT Announces 2023 Financial Calendar**

**Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 2023** **– GENFIT (Nasdaq and Euronext: GNFT)**, a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023.

**2023 Financial Calendar**

---

| | |
|:---|:---|
| &nbsp;&nbsp;February 28, 2023 | &nbsp;&nbsp; Publication of revenue and cash position at<br> December 31, 2022 |
| &nbsp;&nbsp;April 13, 2023 | &nbsp;&nbsp; Publication of Full Year 2022 financial statements<br>*The 2022 Universal Registration Document and Annual Financial Report (included in the Universal Registration Document), as well as the Annual Report on Form 20-F will be made public*<br> *by the end of April 2023.* |
| &nbsp;&nbsp;May 11, 2023 | &nbsp;&nbsp; Publication of revenue and cash position at<br> March 31, 2023 |
| &nbsp;&nbsp;May 24, 2023 | Annual Shareholders Meeting |
| &nbsp;&nbsp;September 20, 2023 | &nbsp;&nbsp; Publication of the half-year 2023 financial<br> statements |
| &nbsp;&nbsp;November 9, 2023 | &nbsp;&nbsp; Publication of revenue and cash position at<br> September 30, 2023 |

---

This calendar is subject to change.

**ABOUT GENFIT**

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.

Its R&D pipeline covers five therapeutic areas via six independent programs which explore the potential of differentiated mechanisms of action, across a variety of development stages (Phase 1,

![](footer.jpg)

![](hdr.jpg)

Phase 2, Phase 3). These diseases are acute on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorder (UCD)/organic acidemia disorder (OAD) and primary biliary cholangitis (PBC). Beyond therapeutics, GENFIT's pipeline also includes a diagnostic franchise focused on NASH and ACLF.

GENFIT has facilities in Lille and Paris, France, Zurich, Switzerland, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext's regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT's largest shareholders and holds 8% of the company's share capital. www.genfit.com

**FORWARD LOOKING STATEMENTS**

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT's research and development programs and planned release of financial information. The use of certain words, including "consider", "contemplate", "think", "aim", "expect", "understand", "should", "aspire", "estimate", "believe", "wish", "may", "could", "allow", "seek", "encourage" or "have confidence" or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations, potential synergies related to the acquisition of Versantis and our capacity to integrate its assets and develop its programs, and our continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Main Risks and Uncertainties" of the Company's 2021 Universal Registration Document filed with the AMF on April 29 2022 under n° D.22-0400, which is available on the Company's website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC") including the Company's 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022 and the 2022 Half-Year Business and Financial Report. In addition, even if the Company's results, performance, financial

![](footer.jpg)

![](hdr.jpg)

condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

**CONTACT**

**GENFIT** \| Investors

Tel: +33 3 2016 4000 \| investors@genfit.com

**PRESS RELATIONS** \| Media

Stephanie Boyer – Press relations \| Tel: +333 2016 4000 \| stephanie.boyer@genfit.com

![](footer.jpg)